Nektar Therapeutics financials at a glance

Year Year 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Rev. Revenue
$114.27M $126.28M $217.72M $273.03M $90.19M $71.93M $159.04M $71.48M $81.19M $148.92M $200.71M $230.78M $165.44M $307.71M $1.19B $114.62M $152.92M $101.91M $92.06M $0.00M $0.00M
GM % Gross Margin %
82.67% 71.49% 45.76% 46.33% 62.67% 56.98% 83.86% 69.37% 62.52% 74.14% 85.78% 85.22% 81.74% 90.07% 97.95% 81.35% 87.26% 75.57% 76.50% 0.00% 0.00%
OM Operating Margin
-64.71% -86.66% -60.68% -28.77% -161.66% -132.25% -9.86% -169.61% -171.85% -80.67% -8.21% -12.73% -68.22% -14.19% 57.65% 0.00% -248.45% 0.00% -260.97% 0.00% 0.00%
EPS Earnings Per Share
$-1.30 $-1.22 $-0.81 $-0.37 $-1.11 $-0.27 $-1.19 $-1.48 $-1.40 $-0.42 $-0.51 $-1.10 $-0.62 $3.78 $-2.52 $-2.49 $-2.86 $-1.97 $-0.86 $0.00
Div. Dividends
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
PR % Payout Ratio %
0 -0.00% -0.00% -0.00% 0 -0.00% -0.00% -0.00% -0.00% -0.00% -0.00% 0 0 0 0.00% -0.00% -0.00% -0.00% -0.00% -0.00% 0
Sha. Shares
83.97m 87.62m 90.3m 92.19m 92.45m 93.2m 94.33m 114.43m 115.17m 116.12m 128.44m 133.45m 152.84m 157.47m 173.09m 175.92m 179.4m 182.3m 184.56m 190.77m 190.77m
OCF Operating Cash Flow
$-78.14M $-78.00M $-92.72M $146.30M $-145.78M $39.74M $-55.87M $-113.74M $-129.76M $-38.53M $-142.01M $-73.08M $-117.02M $-80.41M $718.21M $-328.68M $-313.29M $-412.66M $-304.01M $0.00M $0.00M
FCF Free Cash Flow
$-105.33M $-95.96M $-115.24M $113.50M $-164.64M $19.04M $-87.33M $-123.46M $-140.34M $-42.62M $-151.98M $-84.28M $-123.42M $-90.09M $706.61M $-354.97M $-320.55M $-427.65M $-309.68M $-281.00M $0.00M
FCFS Free Cash Flow Per Share
$-1.34 $-1.12 $-1.28 $1.24 $-1.78 $0.21 $-0.93 $-1.09 $-1.22 $-0.37 $-1.20 $-0.64 $-0.88 $-0.58 $4.15 $-2.03 $-1.79 $-2.33 $-1.65 $0.00 $0.00